Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between orally administered tyramine and moclobemide.

R Zimmer1, A J Puech, F Philipp

  • 1Pharma Clinical Research, F. Hoffmann-La Roche, Basle, Switzerland.

Acta Psychiatrica Scandinavica. Supplementum
|January 1, 1990
PubMed
Summary

Ingesting tyramine with food significantly increases the required dose to raise blood pressure compared to fasting. Tranylcypromine poses a greater risk than moclobemide due to potentiation of tyramine

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurements of top-quark pair differential cross-sections in the lepton+jets channel in <i>pp</i> collisions at [Formula: see text] using the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for squarks and gluinos in events with hadronically decaying tau leptons, jets and missing transverse momentum in proton-proton collisions at [Formula: see text] TeV recorded with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for squarks and gluinos in final states with jets and missing transverse momentum at [Formula: see text] =13 [Formula: see text]with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for new phenomena in events containing a same-flavour opposite-sign dilepton pair, jets, and large missing transverse momentum in [Formula: see text] [Formula: see text][Formula: see text] collisions with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Electron efficiency measurements with the ATLAS detector using 2012 LHC proton-proton collision data.

The European physical journal. C, Particles and fields·2017
Same author

Measurements of top-quark pair differential cross-sections in the [Formula: see text] channel in <i>pp</i> collisions at [Formula: see text] TeV using the ATLAS detector.

The European physical journal. C, Particles and fields·2017

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Nutritional Science

Background:

  • Tyramine ingestion can cause dangerous blood pressure increases, especially with monoamine oxidase inhibitors (MAOIs).
  • Standardized oral tyramine pressor tests are crucial for assessing real-world food-drug interactions.

Purpose of the Study:

  • To evaluate the safety of oral tyramine ingestion with food in individuals taking MAOIs.
  • To compare the pressor effects of tyramine with moclobemide and tranylcypromine.

Main Methods:

  • A standardized oral tyramine pressor test was developed for food-ingestion scenarios.
  • Healthy volunteers were tested under fasting and fed conditions, with and without moclobemide or tranylcypromine.

Main Results:

Related Experiment Videos

  • Significantly higher tyramine doses were needed to raise blood pressure by 30 mmHg (TYR 30) when ingested with food versus fasting.
  • Tranylcypromine (10 mg TID) showed a 7.6-fold greater potentiation of tyramine's pressor effect compared to moclobemide (200 mg TID).
  • Protein-rich or lipid-rich meals reduced the pressor effect of tyramine.

Conclusions:

  • Tyramine ingestion with food reduces the risk of hypertensive crises compared to fasting, especially with MAOIs.
  • Tranylcypromine poses a significantly higher risk of tyramine-induced hypertension than moclobemide, even with food.
  • Dietary tyramine limits are critical for patients on MAOIs, with low doses posing risks for tranylcypromine users.